REDEFINE 1: CagriSema improves blood pressure and body composition

Introduction

Obesity is a complex, multifactorial disease closely linked to cardiovascular comorbidities such as high blood pressure. In this context, drug treatment plays a central role in achieving sustained weight loss and metabolic improvements.

During Obesity Week 2025, the results of the REDEFINE 1 study were presented, a phase 3a, double-blind, controlled trial that evaluated the combination of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) in 3,417 adults who were overweight or obese without diabetes.

The findings highlighted consistent clinical benefits in body composition, physical function, and blood pressure, positioning CagriSema as an innovative therapeutic option for the comprehensive treatment of obesity.

Body composition and physical function

In the subanalysis led by Ravussin et al., 252 participants were evaluated using dual-energy X-ray absorptiometry (DXA).

The results showed that 67% of total weight loss was attributed to fat mass reduction, while lean tissue proportion increased, demonstrating a qualitative improvement in body composition.

After 68 weeks, participants treated with CagriSema reduced their body weight by –22.7% (–24.1 kg), compared to –2.3% (–2.5 kg) in the placebo group.

In addition, a significant improvement in physical function and quality of life was observed, reflected in the scores:

IWQOL-Lite-CT: +26.9 vs. +14.1 (p<0.001)

SF-36v2: +7.4 vs. +3.4 (p<0.001)

These results suggest that reducing body fat directly translates into greater mobility, emotional well-being, and functional capacity.

Effects on blood pressure

The analysis by Verma et al. showed that CagriSema produced clinically relevant reductions in blood pressure, even in patients undergoing antihypertensive treatment.

Mean decrease in systolic pressure: –10.9 mmHg

Mean decrease in diastolic pressure: –5.3 mmHg

(vs. –2.1 and –1.4 mmHg in placebo)

Among participants using antihypertensive drugs:

39.6% of the CagriSema group reduced or discontinued their medication, compared to 18.8% in the placebo group.

In resistant hypertension, 42% achieved <130/80 mmHg, compared with 29.3% in the placebo group (OR 1.7; 95% CI 0.7–4.4).

These results consolidate CagriSema as a dual therapy capable of improving blood pressure control and reducing drug dependence, contributing to a more comprehensive management of cardiovascular risk.

Conclusion

The REDEFINE 1 study demonstrates that CagriSema 2.4 mg/2.4 mg represents a significant therapeutic advance for obesity, combining substantial and sustained weight reduction, improvements in body composition, and a significant decrease in blood pressure.

The results reinforce the concept of obesity as a systemic disease that requires combined approaches, with a direct impact on cardiometabolic health.

 Referencias

1. Ravussin E., Osorto Contreras C.K., Frühbeck G., et al. REDEFINE 1: Effect of CagriSema 2.4 mg/2.4 mg on body composition, muscle strength & physical function. Presentado en: Obesity Week 2025, Abstract Oral-056.
2. Verma S., Böttcher M., Brown P., et al. CagriSema reduces blood pressure in adults with overweight or obesity: the REDEFINE 1 trial. Presentado en: Obesity Week 2025, Abstract Oral-055.
3. Kushner R.F., et al. (2024). Advances in GLP-1 and dual agonist therapies for obesity management. New England Journal of Medicine, 391(6), 521–533.
4. American Heart Association. (2024). Hypertension and obesity: integrated management strategies. Circulation, 149(7), 580–592.

Nota editorial: Este contenido ha sido desarrollado con el apoyo de tecnologías de inteligencia artificial para optimizar la redacción y estructuración de la información. Todo el material ha sido cuidadosamente revisado, validado y complementado por expertos humanos antes de su publicación, lo que garantiza su precisión científica y su adecuación a las buenas prácticas editoriales.